The Biological Activity of Cediranib (AZD2171) in Gastro-Intestinal Stromal Tumours(GIST).
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
To determine the anti-tumour activity and biological effects of cediranib (AZD2171) at a dose
of 45mg, primarily in Gastrointestinal Stromal Tumour (GIST) patients who are resistant to
imatinib mesylate (current standard therapy) and also in patients with metastatic Soft Tissue
Sarcoma (STS) resistant to standard therapy.